[HTML][HTML] Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for …
Parametric mapping techniques provide a non-invasive tool for quantifying tissue alterations
in myocardial disease in those eligible for cardiovascular magnetic resonance (CMR) …
in myocardial disease in those eligible for cardiovascular magnetic resonance (CMR) …
[HTML][HTML] Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the …
Rapid innovations in cardiovascular magnetic resonance (CMR) now permit the routine
acquisition of quantitative measures of myocardial and blood T1 which are key tissue …
acquisition of quantitative measures of myocardial and blood T1 which are key tissue …
Developing therapies for heart failure with preserved ejection fraction: current state and future directions
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is
projected to worsen. To date, there are no approved therapies available for reducing …
projected to worsen. To date, there are no approved therapies available for reducing …
Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis
M Fontana, S Pica, P Reant, A Abdel-Gadir, TA Treibel… - Circulation, 2015 - Am Heart Assoc
Background—The prognosis and treatment of the 2 main types of cardiac amyloidosis,
immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially …
immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially …
Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality
TC Wong, K Piehler, CG Meier, SM Testa, AM Klock… - Circulation, 2012 - Am Heart Assoc
Background—Extracellular matrix expansion may be a fundamental feature of adverse
myocardial remodeling, it appears to be treatable, and its measurement may improve risk …
myocardial remodeling, it appears to be treatable, and its measurement may improve risk …
Myocardial interstitial fibrosis in heart failure: biological and translational perspectives
Myocardial interstitial fibrosis contributes to left ventricular dysfunction leading to the
development of heart failure. Basic research has provided abundant evidence for the …
development of heart failure. Basic research has provided abundant evidence for the …
Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart …
Aims Diabetes may promote myocardial extracellular matrix (ECM) expansion that increases
vulnerability. We hypothesized that:(i) type 2 diabetes would be associated with quantitative …
vulnerability. We hypothesized that:(i) type 2 diabetes would be associated with quantitative …
Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults
Context Unrecognized myocardial infarction (MI) is prognostically important.
Electrocardiography (ECG) has limited sensitivity for detecting unrecognized MI (UMI) …
Electrocardiography (ECG) has limited sensitivity for detecting unrecognized MI (UMI) …
[HTML][HTML] Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus …
EB Schelbert, SM Testa, CG Meier, WJ Ceyrolles… - Journal of …, 2011 - Elsevier
Background Myocardial extravascular extracellular volume fraction (Ve) measures quantify
diffuse fibrosis not readily detectable by conventional late gadolinium (Gd) enhancement …
diffuse fibrosis not readily detectable by conventional late gadolinium (Gd) enhancement …
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
GA Lewis, S Dodd, D Clayton, E Bedson, H Eccleson… - Nature Medicine, 2021 - nature.com
In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial
fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent …
fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent …